AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02269072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert cream otherwise identical to testosterone cream applied daily for two weeks
Study NCT02784834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Study NCT03217994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gel HP
Description: gel of hygrogen peroxide for teeth bleaching
Study NCT03217994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gel HP
Description: gel of hygrogen peroxide for teeth bleaching
Study NCT04596748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Bacillus Subtilis, Bacillus Clausii, Bacillus Coagulans, Bacillus Indicus HU36, MCC 102
Study NCT04596748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo caps
Study NCT05196555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair of cleft palate with intravelar veloplasty (IVVP)
Description: A triangular flap is designed comprising new epithelial tissue which will be turned over to help close the nasal mucosa. Using a single hook, the oral mucosa and gland layer is separated from the muscle layer. Dissection of the greater palatine nerve-vessel bundle. The anterior palatal flap is raised by a curved elevator. The closure of the nasal mucosa and muscle is completed. Dissection of Velo Palatine Levator begins from the posterior rim of muscle and 5 mm from the midline.
Study NCT01185977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter
Study NCT01185977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill of PBO for 4 days then two pills of PBO thereafter
Study NCT03615339 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Molkosan
Description: Twice daily (AM and PM) 20ml of fermented whey concentrate consumed diluted in 200ml water
Study NCT04488016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A- Part 1
Description: Subjects will receive 100 mg acalabrutinib capsule, fasted state;
Study NCT04488016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B- Part 1
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
Study NCT04488016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - Part 1
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
Study NCT04488016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D- Part 1
Description: Subjects will receive Rabeprazole 20 mg QD (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1) and following prior administration of rabeprazole 20 mg Twice per day (BID) (with meals) on Days -3, -2 and -1.
Study NCT04488016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A-Part 2
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
Study NCT04488016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - Part 2
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 2), fasted state
Study NCT04488016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - Part 2
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 3), fasted state
Study NCT04488016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D - Part 2
Description: Subjects will receive 100 mg acalabrutinib solution, (Variant 4), fasted state
Study NCT02831933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADV/HSV-tk
Description: Replication-defective recombinant adenovirus vector
Study NCT02831933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Prodrug of the antiviral drug acyclovir
Study NCT02831933 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Low-dose SBRT
Study NCT02831933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody
Study NCT04358965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous tranexamic acid
Description: patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
Study NCT04358965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal misoprostol
Description: patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
Study NCT04358965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
Study NCT01613703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2952
Description: 1 mg to 200 mg QD at a single descending dose
Study NCT01548508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functionnal ElectroStimulation (FES)
Description: Functionnal ElectroStimulation on lower limbs, 1h per day, 5 days per 7, during 6 weeks
Study NCT01548508 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: SHAM on lower limbs, 1h per day, 5 days per 7, during 6 weeks
Study NCT02687100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Description: beclometasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning
Study NCT02687100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive 8 mL of saline without any drug
Study NCT02990039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling letter
Description: The intervention is based on the Health Action Process Approach. The first letter provides information on knowledge regarding sedentary time and physical activity as well as intervenes on self-efficacy depending on the mindset of participants (non-intender, intender, actor). The second letter focuses on benefits and barriers of physical activity as well as the role of social support for physical activity. In case of actional stage, the third letter intervenes on self-efficacy again and suggests action and coping planning. Otherwise, the letter includes ipsative feedback according to the second letter.
Study NCT00129129 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose
Study NCT00129129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ActHIB
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose
Study NCT00129129 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediarix
Description: Primary phase: 3 IM doses
Study NCT00129129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix
Description: Primary phase: 3 IM doses
Study NCT00129129 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose
Study NCT00129129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose
Study NCT00129129 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menomune
Description: Primary phase: 1 SC dose
Study NCT00924872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wheelchair skills training
Description: Five 30-minute training sessions, at a target frequency of 3-5 sessions per week, aimed at improving their power wheelchair skills.
Study NCT04264468 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: neoadjuvant chemotherapy
Description: This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.Based on the Mammaprint technology analysis of patients with pathologic complete response (pCR), partial response and no response, we analyzed the characteristic genes related to breast cancer in the tumor tissues and evaluated the accuracy and sensitivity of the Mammaprint test for the efficacy of neoadjuvant chemotherapy
Study NCT01758380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Patients will be instructed to take Vildagliptin tablets at a fixed dose of 50 mg twice daily (double blind therapy)
Study NCT01758380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide
Description: Patients will be instructed to take Gliclazide capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
Study NCT01758380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion
Study NCT01758380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion
Study NCT02056327 — intervention group
Intervention type: DEVICE
Intervention: A novel monitoring suite of sensors will be inserted into the standard oral device.
Study NCT01758380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Gliclazide
Description: Patients will be instructed to take the Gliclazide matching placebo capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
Study NCT01758380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Vildagliptin
Description: Patients will be instructed to take Vildagliptin matching placebo tablets at a fixed dose of 50 mg twice daily (double blind therapy).
Study NCT01094691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Allograft Biopsy
Description: A renal allograft biopsy will be performed when the urine is determined to be Haufen negative.
Study NCT03131440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.
Study NCT00975949 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Parents of subjects were interviewed and two surveys were obtained, the Child Health Questionnaire and the Vineland-II.
Study NCT01992211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
Study NCT01992211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
Study NCT01042561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 400 IU of vitamin D3 daily. Pts will recieve 1 mL a day with a feeding for 28 days.
Study NCT01042561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D3 placebo
Description: Placebo designed by research pharmacist. Pts will recieve 1 mL a day with feedings for 28 days.
Study NCT00669253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er: YAG Laser
Description: Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
Study NCT00669253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment 1(ultrasonic and manual means)
Description: Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods : ultrasonic and manual means
Study NCT00669253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment 2 (ultrasonic and manual means)
Description: Surgery at baseline for all deep pockets using conventional methods: ultrasonic and manual means
Study NCT01410721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation Intervention
Description: Baseline training and follow-up at two months and four months.
Study NCT01410721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Rehabilitation Control Intervention
Description: Baseline training and follow-up at two months and four months.
Study NCT02245620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elamipretide
Description: Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
Study NCT02245620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
Study NCT00833599 — intervention group
Intervention type: DRUG
Intervention: NIRFLI with ICG
Description: We conduct Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic trafficking in subjects. We seek to use the resulting phenotypes acquired in normal and diseased patients to correlate to mutations of specific genes reported to be associated with lymphatic development.
Study NCT01992211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCWP_C003
Description: Participant will be administered a single oral dose of BCWP_C003 under Fasting condition or Fed condition according to sequence.
Study NCT03131440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Calls
Description: Participants will receive 6 bi-weekly phone calls from study staff.
Study NCT03131440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App+
Description: Participants will receive deluxe version of smartphone app with additional features.
Study NCT05063175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy Protocol
Description: The conventional physical therapy protocol was prescribed to correct the kyphotic posture of the dorsal spine, and improve postural balance stability during standing and walking. The conventional therapeutic protocol for every child was three sessions per week for 12 successive weeks. Every treatment session was applied for two hours with a few minutes rest in between them.
Study NCT03131440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.
Study NCT05063175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy Protocol
Description: The conventional physical therapy protocol was prescribed to correct the kyphotic posture of the dorsal spine, and improve postural balance stability during standing and walking. The conventional therapeutic protocol for every child was three sessions per week for 12 successive weeks. Every treatment session was applied for two hours with a few minutes rest in between them.
Study NCT05063175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraTog orthotic undergarment with its strapping system
Description: TheraTog orthotic undergarment with its strapping system was conducted for 8 hours daily for 12 successive weeks. It is made to be fitted directly on the skin as undergarments.
Study NCT03039322 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Golgi Protein 73
Description: Serum test
Study NCT03131440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App notifications
Description: Participants will receive motivational app notifications
Study NCT01192568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: 10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.
Study NCT01192568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical gel
Study NCT01022424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Description: Repeated oral administration at doses of 15 mg twice daily (morning and evening)
Study NCT00133666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Communication Education
Study NCT00133666 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Asthma Education
Study NCT03010280 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: Balanced high-protein formula enriched with Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
Study NCT03010280 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Balanced high-protein formula
Description: Balanced high-protein formula, without Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
Study NCT03416127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
Study NCT03416127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
Study NCT03416127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.
Study NCT01971008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic abdominal binder
Study NCT01971008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo binder
Study NCT01462617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557
Description: Study Drug
Study NCT01462617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK2269557 matching placebo
Description: Study Drug
Study NCT00495625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles will be 37.5 mg daily for 28 days, every 42 days. Dose may be escalated to 50 mg daily for 28 days at the treating investigator's discretion.
Study NCT01012544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
Study NCT01712425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0-24 week prime/boost regimen
Description: ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly
Study NCT01712425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0-8 week prime/boost regimen
Description: ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly
Study NCT02591485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Training
Description: In the ACT, participants perform six computerized attention training sessions, 10 minutes per training session over six weeks. In each session the dot-probe task is administered. This task is consisted of 160 trials. Each trial began with a centrally-presented fixation cross that then replaced by a pair of words presented. Following that, a target probe appeared in the location previously occupied by one of the words, and participants are requested to discriminate the probe type via button press. Targets appear with equal probability at the location of threat and neutral stimuli, in order to modify the fluctuations in attention allocation.
Study NCT03842449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BabyCO
Description: An expired CO measurement will be performed by BabyCO and the result will be returned to the smoking pregnant woman by the consultant.
Study NCT03131440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy
Description: Participants will choose a buddy to receive a Fitbit and support them during the intervention.
Study NCT02166723 — intervention group
Intervention type: DEVICE
Intervention: Cryoballoon Ablation
Description: . The goal was to isolate all 4 veins with application of cryoballoon on the ostium of the vein. A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. . In each patient the left atrium was debulked by applying cryoballoon